IAC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Based on the provided data, IAC Inc is not a strong buy for a beginner investor with a long-term focus. The company's financial performance shows significant declines in revenue, net income, and EPS, and there are no recent positive news catalysts. Additionally, hedge funds are selling, and options data suggests bearish sentiment. While analysts have raised price targets, the overall sentiment is mixed, and there are no strong proprietary trading signals to support an immediate buy decision. For a long-term investor, it would be prudent to wait for clearer positive catalysts or improved financial performance before considering an investment in IAC.
The MACD histogram is positive and expanding, indicating a bullish trend. RSI is neutral at 65.574, and moving averages are converging, suggesting no clear directional bias. The stock is trading near its resistance level (R1: 37.664, R2: 38.829), which could limit further upward movement in the short term.
Analysts have raised price targets recently, with Citi and Jefferies maintaining a Buy rating. Traffic headwinds for People are expected to ease through 2026, and MGM's performance could act as a potential catalyst.
Hedge funds are selling heavily, with a 304.76% increase in selling activity. Financial performance has deteriorated significantly, with revenue, net income, and EPS all showing steep declines. Options data indicates bearish sentiment with a high put-call ratio. No recent news or congress trading data to provide positive momentum.
In Q4 2025, revenue dropped by 34.70% YoY to $645.98M, net income fell by 61.41% YoY to -$76.79M, and EPS declined by 58.58% YoY to -$0.99. Gross margin also decreased by 2.80% YoY to 64.97%.
Analysts have mixed views. Citi raised the price target to $44 and maintains a Buy rating. UBS raised the target to $42 but remains Neutral, citing valuation concerns. Oppenheimer downgraded the stock to Perform, citing minimal upside and lack of near-term catalysts. JPMorgan and Jefferies raised price targets to $46 and $45, respectively, with Buy ratings.
